Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 6Phase 3 3Phase 1/2 2Phase 4 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1

Interventions

Dexamethasone 169Bortezomib 92Lenalidomide 85daratumumab 44Thalidomide 44pomalidomide 43Melphalan 40Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14isatuximab 12Filgrastim 12ixazomib 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5iberdomide 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × talquetamab × Clear all
NCT05552222 2026-06-05

MajesTEC-7

Janssen Research & Development, LLC

Phase 3 Recruiting
1,590 enrolled
Plasma cell

Multiple Myeloma

NCT06208150 2026-06-05

MonumenTAL-6

Janssen Research & Development, LLC

Phase 3 Recruiting
795 enrolled
Plasma cell

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
864 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡